Výsledky vyhledávání

Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis

Autor: Willem J Lammers, George F. Mells, Maren H. Harms, Bettina E. Hansen, David Jones, R. Pencek, Leigh MacConell, David Shapiro, T. Marmon, Marco Carbone

Publikováno v: Hepatology Communications
Hepatology Communications, 2(6), 683-692. Wiley-Blackwell Publishing Ltd

The GLOBAL Primary Biliary Cholangitis (PBC) Study Group and United Kingdom-PBC (UK-PBC) Consortium have demonstrated that dichotomous response criteria are not as accurate as continuous equations at predicting mortality or liver transplantation in P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788b0e84858a81c7f7732f6cd7d19649
https://pure.eur.nl/en/publications/92725145-bea3-4fc8-9b7f-58df542dbc1b

Zobrazit plný text záznamu

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

Autor: Nicholas F. LaRusso, Thomas D. Schiano, David Shapiro, Kris V. Kowdley, Raj Vuppalanchi, David S. Goldberg, Leigh MacConell, Gideon M. Hirschfield, Aesop Study Investigators, R. Pencek, James F. Trotter, Roshan Shrestha, Simon M. Rushbrook, Yuying Jin, Christopher L. Bowlus, Annarosa Floreani, Pietro Andreone, Cynthia Levy

Publikováno v: Journal of hepatology
Journal of hepatology, vol 73, iss 1

Background & Aims: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a5e016f8f9d08cb8dae3ba936d34c09
https://hdl.handle.net/11380/1249318

Zobrazit plný text záznamu

ATU-09 Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis

Autor: Christopher L. Bowlus, Luigi Terracciano, Stephen D. Ryder, Alexander Liberman, R. Pencek, Paul J. Pockros, Yuying Jin, Joost P.H. Drenth, Lisa Forman, Pierre Bedossa, Albert Parés, Andreas E. Kremer, Leigh MacConell

Publikováno v: Abstracts of Distinction.

Introduction Obeticholic acid (OCA) is a potent, selective FXR agonist approved for the treatment of PBC based upon biochemical improvements predicted to improve transplant-free survival. An optional liver biopsy substudy was conducted in a subset of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c67886666d2a1c89349a93acc84bc391
https://doi.org/10.1136/gutjnl-2019-bsgabstracts.209

Zobrazit plný text záznamu

PTU-100 Efficacy of obeticholic acid treatment in patients with primary biliary cholangitis with cirrhosis

Autor: R. Pencek, John M. Vierling, D.E.J. Jones, Roberto J. Groszmann, Gideon M. Hirschfield, Kris V. Kowdley, T. Marmon, Leigh MacConell

Publikováno v: Liver.

Introduction Obeticholic acid (OCA) is a potent and selective farnesoid X receptor (FXR) agonist under investigation for treatment of primary biliary cholangitis (PBC) and other chronic liver diseases. POISE was a double-blind, placebo-controlled, ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5dfb6049c1218f929af88f3999ff780
https://doi.org/10.1136/gutjnl-2017-314472.195

Zobrazit plný text záznamu

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Autor: Mitchell L. Shiffman, Frederik Nevens, Joost P.H. Drenth, Christopher L. Bowlus, Leigh MacConell, R. Pencek, Gideon M. Hirschfield, Pietro Andreone, David Shapiro, Victor Vargas, Michael Trauner, Elizabeth Smoot Malecha

Publikováno v: Lancet Gastroenterology & Hepatology, 4, 6, pp. 445-453
Lancet Gastroenterology & Hepatology, 4, 445-453

Item does not contain fulltext BACKGROUND: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aca6526c5076df23d22007c4717aad7
https://hdl.handle.net/2066/205170

Zobrazit plný text záznamu

PWE-080 Change in bilirubin with obeticholic acid in primary biliary cholangitis patients with high baseline bilirubin

Autor: Elizabeth Smoot Malecha, Albert Parés, Leigh MacConell, Mitchell L. Shiffman, David Shapiro, Gideon M. Hirschfield, R. Pencek

Publikováno v: Liver.

Introduction In patients with primary biliary cholangitis (PBC), bilirubin (BILI) is a recognised marker of disease progression and a strong predictor of survival. Recently, the Global PBC Study Group reported risk with elevated BILI extends into the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4ba8fb1bc13ebbf99ae744b726cfd4b
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.222

Zobrazit plný text záznamu

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

Autor: Christopher L. Bowlus, R. Pencek, Luigi Terracciano, Leigh MacConell, Andreas E. Kremer, Albert Parés, Alexander Liberman, Yuying Jin, Lisa Forman, Pierre Bedossa, Paul J. Pockros, Uche Iloeje, Joost P.H. Drenth, Stephen D. Ryder

Publikováno v: Clinical Gastroenterology and Hepatology, 18, 1170-1178.e6
Clinical Gastroenterology and Hepatology, 18, 5, pp. 1170-1178.e6

Background & Aims Primary biliary cholangitis (PBC) is an autoimmune disease characterized by bile duct destruction that can progress to cirrhosis. A liver biopsy substudy was conducted in the PBC obeticholic acid (OCA) International Study of Efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e346f9d201173961c58a792cf15a50
https://doi.org/10.1016/j.cgh.2019.09.050

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání